IGHE and asthma: In regard to allergic patients with severe asthma previously uncontrolled by anti-IgE therapy, the present multi-center real-life experience clearly suggests that switching from omalizumab to benralizumab can induce significant improvements related to important clinical, functional, and biological aspects.